GlassScriptPhysician profile
Candace Schaefer Sanders
NPI 1205218419
$1,811.31
in general payments reported to CMS, 2019-2025
13 companies · $97.08 in 2025
The $97.08 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.87 · 2022: $160 · 2023: $149 · 2024: $1,378 · 2025: $97.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313 · Travel and Lodging: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.24 |
| Travel and Lodging | $311.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $793.76 | 2024 | |
| Ucb, INC. | $168.19 | 2024 | Briviact, Fintepla |
| Jazz Pharmaceuticals INC. | $163.70 | 2024 | |
| Immedica Pharma US, INC. | $147.61 | 2024 | |
| Lilly USA, LLC | $135.59 | 2022-2023 | Emgality, Reyvow |
| Sk Life Science, INC. | $131.25 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $70.06 | 2022 | |
| Pfizer INC. | $64.92 | 2023-2025 | |
| Abbvie INC. | $58.28 | 2021-2023 | Qulipta, Ubrelvy |
| Medtronic, INC. | $25.23 | 2024 | Percept PC Brainsense |
| Livanova USA, INC. | $19.45 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Owp Pharmaceuticals, INC. | $17.86 | 2023 | Lamotrigine, Subvenite |
| Amgen INC. | $15.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.